QPPV.COM KNOWLEDGE ASSESSMENT

Ivonescimab: Classification, Evidence, Safety and Pharmacovigilance Assessment

Test your understanding of the concepts covered by Ivonescimab: Classification, Mechanism, Evidence and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the appropriate pharmacovigilance approach to reconciling clinical-trial and post-authorisation safety information?

Reconcile them according to applicable procedures while preserving the context of each source Always treat the clinical-trial record as a duplicate and discard it Combine the sources without reconciliation because they describe the same medicine Use only post-authorisation reports because trial information cannot support safety evaluation

Question 2 of 10 Which description best characterises ivonescimab’s pharmacological design?

A humanised bispecific IgG1 antibody that binds PD-1 and VEGF-A A monoclonal antibody that binds PD-1 and carries a cytotoxic payload A small-molecule inhibitor that blocks EGFR and VEGF-A A fusion protein that binds EGFR and delivers chemotherapy

Question 3 of 10 Why should signal assessment account for exposure time and treatment interruptions?

Because patients may have different opportunities for an event to occur and interruptions alter exposure patterns Because exposure time determines whether an event is serious Because treatment interruptions prove that an event was caused by the medicine Because exposure adjustment eliminates the need for clinical case review

Question 4 of 10 A safety team observes events in a population studied in a trial but not included in the described China NMPA indication. How should it describe that evidence?

As evidence relevant to the broader research programme, not as an authorised indication unless a regulator has approved the change As proof that the China-authorised indication includes all NSCLC populations As evidence that the NMPA indication is no longer applicable As irrelevant to pharmacovigilance because it falls outside the authorised population

Question 5 of 10 Which statement most accurately describes PD-1 biology as relevant to ivonescimab?

PD-1 is a vascular growth factor that promotes angiogenesis PD-1 is an inhibitory receptor on immune cells, and ligand engagement can attenuate T-cell activity PD-1 is a tumour-specific antigen whose presence guarantees response to treatment PD-1 is the cytotoxic payload released by antibody-drug conjugates

Question 6 of 10 Which is the most defensible interpretation of the higher proportion of grade 3 or higher immune-related events reported in the ivonescimab arm of HARMONi-A?

It is a study-specific comparative observation that merits context and review, not proof that every such event was caused by ivonescimab It proves that all immune-related events in the study were caused by PD-1 blockade It establishes the frequency expected in every population and regimen It demonstrates that VEGF-A binding prevents chemotherapy-related toxicity

Question 7 of 10 Which approach is most appropriate for aggregate safety review of ivonescimab?

Stratify events by event class, exposure, tumour population and concomitant chemotherapy while keeping competing causal hypotheses distinct Combine all events into one category because the treatment targets two pathways Attribute every event to ivonescimab if it occurs after the first dose Review event counts without considering treatment exposure or the tumour population

Question 8 of 10 Which practice best supports an auditable safety assessment when new information becomes available?

Preserve alternative causes and document how the assessment changes as evidence accumulates Retain only the final causality category and remove earlier reasoning Avoid follow-up if the initial report contains a suspected medicine Replace the original case narrative with a single preferred explanation

Question 9 of 10 A case report attributes an event to ivonescimab solely because it began after treatment started. What is the principal weakness of this assessment?

Temporal association alone does not distinguish the medicine’s contribution from infection, progression, chemotherapy or other causes An event occurring after treatment starts can never be related to the medicine Causality can only be assessed after overall-survival data mature The case must be excluded because the patient has cancer

Question 10 of 10 For a suspected immune-mediated event, which additional information is particularly valuable in the case narrative?

Diagnostic reasoning and the patient’s response to immunosuppression Only the brand name of the chemotherapy Only the number of tumour lesions before treatment Whether the event occurred during a weekday or weekend

QPPV.com

Ivonescimab: Classification, Evidence, Safety and Pharmacovigilance Assessment

Cookie Settings